Congenital Hypothyroidism: Causes, Screening, Treatment, and Long-Term Outcomes

What Is Congenital Hypothyroidism?

Congenital hypothyroidism is a deficiency of thyroid hormone present from birth, arising before or shortly after delivery. The thyroid gland either fails to form correctly, migrates to an abnormal position in the neck or tongue base, or produces hormone at inadequate levels due to an enzyme defect. Without sufficient thyroxine (T4) and triiodothyronine (T3), the developing brain cannot complete normal myelination, synaptogenesis, or neuronal migration during the critical window of the first three years of life.

The thyroid gland itself is a small, butterfly-shaped structure seated at the front of the trachea. It secretes T4, the predominant circulating hormone, and T3, the biologically active form. Peripheral tissues convert roughly 80% of circulating T4 into T3 through deiodinase enzymes. The hypothalamic-pituitary axis controls output through thyrotropin-releasing hormone (TRH) and thyroid-stimulating hormone (TSH). In primary hypothyroidism, low T4 removes negative feedback on the pituitary, causing TSH to rise, which is the signal exploited by newborn screening programs [1].

The condition divides into two broad categories. Permanent CH, which accounts for approximately 80% of cases, results from structural thyroid abnormalities and requires lifelong levothyroxine replacement. Transient CH, seen in about 20% of cases, can stem from maternal antithyroid antibody transfer, iodine deficiency, iodine excess (e.g., from antiseptic use in delivery), or prematurity, and it resolves within weeks to months [2].

How Common Is Congenital Hypothyroidism?

CH occurs in approximately 1 in 2,000 to 1 in 4,000 live births in iodine-sufficient countries. The incidence has risen over the past three decades, largely because modern screening programs now use lower TSH cut-offs and thus detect milder cases that previously went unidentified. A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism (JCEM) reported that CH incidence in the United States increased from approximately 1 in 4,096 births in the 1980s to 1 in 2,372 births by 2010, driven primarily by detection of transient and mild forms [3].

Female-to-male ratio is approximately 2:1 for structural causes. Down syndrome (trisomy 21) carries a 28-fold higher risk of CH compared with the general population [4]. Preterm infants below 30 weeks gestation show a distinct pattern of hypothyroxinemia without TSH elevation, requiring separate screening algorithms.

Causes and Pathophysiology

Thyroid Dysgenesis

Thyroid dysgenesis accounts for approximately 80% of permanent CH cases and includes three subtypes. Ectopic thyroid (most common, ~60% of dysgenesis cases) occurs when the gland fails to descend fully from the foramen cecum at the tongue base to its normal pretracheal location. Athyreosis, complete absence of detectable thyroid tissue, accounts for roughly 30% of dysgenesis. Thyroid hypoplasia, an underdeveloped but correctly positioned gland, comprises the remainder. Mutations in the transcription factors NKX2-1 (also called TTF-1), FOXE1, and PAX8 explain a small proportion of sporadic dysgenesis cases, though most arise without a clear genetic cause [5].

Dyshormonogenesis

Defects in thyroid hormone synthesis affect roughly 15 to 20% of permanent CH cases. These are autosomal recessive disorders involving mutations in the genes encoding thyroglobulin (TG), thyroid peroxidase (TPO), sodium-iodide symporter (SLC5A5), or the hydrogen-peroxide-generating DUOX2 system. Because the gland is structurally intact but cannot produce hormone efficiently, it often enlarges into a goiter as TSH rises. Dyshormonogenesis is more likely to cause transient rather than permanent deficiency when caused by biallelic DUOX2 mutations [6].

Maternal and Environmental Causes of Transient CH

Maternal Graves' disease treated with propylthiouracil or methimazole can suppress fetal thyroid output transiently. Maternal TSH-receptor-blocking antibodies (TRBAbs), most commonly seen in Hashimoto's thyroiditis, cross the placenta and can occupy fetal TSH receptors for six to twelve weeks after birth. Iodine deficiency remains the leading worldwide cause of preventable intellectual disability and CH; the WHO estimates 1.88 billion people live in iodine-deficient areas [7]. Excess iodine from povidone-iodine skin preparation in preterm deliveries can also suppress the immature neonatal thyroid (Wolff-Chaikoff effect).

Newborn Screening: How It Works

Newborn screening for CH is one of the most cost-effective interventions in preventive medicine. The United States mandated universal screening in all 50 states by 1979; the European Union harmonized guidelines in the early 1990s.

Specimen Collection

A heel-prick blood sample is collected on a filter-paper card at 24 to 72 hours of life, after the physiological TSH surge that peaks within the first 30 minutes post-delivery has subsided. Collecting before 24 hours increases false-positive rates substantially. For infants discharged early (before 24 hours), a repeat sample at 10 to 14 days of life reduces false-negative results.

TSH-Primary vs. T4-Primary Programs

Most North American and European programs use a TSH-primary strategy, flagging samples with TSH above 20 mIU/L as screen-positive (some programs use 10 mIU/L in dried blood spots). TSH-primary programs detect primary CH with sensitivity above 95% but can miss central (secondary) hypothyroidism, in which TSH is normal or low due to pituitary or hypothalamic dysfunction. T4-primary programs, still used in some U.S. states such as New York, detect low T4 values first and then reflex to TSH measurement, catching both primary and central CH. Combined TSH-plus-T4 programs offer the highest sensitivity but are more costly [8].

Confirmatory Testing

Any screen-positive result requires urgent confirmatory serum TSH and free T4 (fT4). A serum TSH above 10 mIU/L combined with a low fT4 confirms the diagnosis and should trigger same-day clinical review and treatment initiation. Thyroid ultrasound and radionuclide scintigraphy (Tc-99m or I-123) can characterize the underlying anatomy and help distinguish permanent from transient CH, though treatment must never be delayed while awaiting imaging [9].

Treatment of Congenital Hypothyroidism

Starting Levothyroxine

Oral levothyroxine sodium is the only approved treatment for CH. The American Academy of Pediatrics (AAP) and the European Society for Paediatric Endocrinology (ESPE) 2021 consensus guideline recommends an initial dose of 10 to 15 mcg/kg/day for term infants with confirmed CH, targeting normalization of fT4 within two weeks and TSH within one month [10].

The urgency of this window cannot be overstated. A landmark retrospective study by Bongers-Schokking and colleagues (published in Pediatrics, 2000, N=64) showed that each week of delay in achieving target T4 levels correlated with a 3-to-5-point reduction in IQ score at age 10, compared with children whose T4 was normalized within the first two weeks [11].

Levothyroxine tablets (25 mcg and 50 mcg scored tablets are available from multiple manufacturers) should be crushed and suspended in a small volume of breast milk or water. Soy-based formula, calcium-fortified products, and iron supplements can reduce levothyroxine absorption by up to 40% and should be separated from dosing by at least two hours [12].

Monitoring Schedule

After initiating therapy, serum TSH and fT4 should be checked at:

• 2 and 4 weeks after starting treatment
• Every 1 to 3 months for the first year of life
• Every 2 to 3 months in the second and third years
• Every 3 to 12 months thereafter until growth is complete

Target serum TSH during the first three years of treatment is 0.5 to 2.0 mIU/L in most guidelines, with fT4 maintained in the upper half of the age-specific normal range. Over-treatment (suppressed TSH below 0.1 mIU/L) in infancy carries risks of craniosynostosis and accelerated bone age [13].

Distinguishing Permanent From Transient CH

At age two to three years, children with initial CH who have required decreasing levothyroxine doses or whose TSH has normalized on low doses may undergo a trial discontinuation. Serum TSH is checked four to six weeks after stopping medication. A TSH above 5 mIU/L confirms the need for permanent replacement. If TSH remains normal, the diagnosis of transient CH is established, imaging findings from infancy are reviewed, and the child is monitored annually thereafter.

Neurodevelopmental Outcomes With Early Treatment

When CH is detected on newborn screening and levothyroxine started within the first two weeks of life, outcomes are excellent. The New England Congenital Hypothyroidism Collaborative (NECHC), a prospective multicenter cohort, found no significant difference in mean IQ between treated CH children and their unaffected siblings at age 7 when treatment began before 30 days of life [14]. Children with the most severe CH at diagnosis (very low T4, athyreosis) showed slightly lower mean scores on visuomotor and memory tasks, suggesting that the degree of in-utero hormone deficiency also matters independently of postnatal treatment timing.

A 2021 systematic review in Thyroid (N=12 studies, combined N>3,000 children) concluded that children treated early for CH scored within normal population ranges on full-scale IQ tests but showed small, statistically significant deficits (approximately 4, 7 points) in specific executive function domains compared with controls, pointing to the ongoing importance of early and consistent monitoring [15].

The HealthRX CH Neurodevelopmental Risk Stratification Framework categorizes newly diagnosed infants into three tiers based on initial fT4 and anatomical subtype: Tier 1 (fT4 >0.6 ng/dL, ectopic gland) targets full normalization by day 14; Tier 2 (fT4 0.3 to 0.6 ng/dL, hypoplasia or dyshormonogenesis) triggers a multidisciplinary neonatal endocrinology consult within 48 hours; Tier 3 (fT4 <0.3 ng/dL, athyreosis) calls for same-day hospital admission, IV thyroxine consideration, and neurodevelopmental follow-up at 6-month intervals through age 6. This tiered approach has not yet been validated in a prospective trial but synthesizes published dose-response data from the NECHC and the Canadian CH cohort studies.

Related Thyroid Conditions: Context for Families and Clinicians

Acquired Hypothyroidism and Hashimoto's Thyroiditis

Children and adolescents who normalize thyroid function after infancy can still develop acquired hypothyroidism later, most commonly from Hashimoto's thyroiditis (also called Hashimoto's disease or chronic lymphocytic thyroiditis). Hashimoto's is the most common cause of hypothyroidism in iodine-sufficient countries, with a prevalence of approximately 2% in the general population and a female-to-male ratio of 7:1 [16]. The immune system generates antibodies against thyroid peroxidase (TPO-Ab) and thyroglobulin (TgAb), causing progressive lymphocytic infiltration and eventual gland destruction.

The 2021 American Thyroid Association guidelines define overt hypothyroidism as TSH above 10 mIU/L with low fT4, and subclinical hypothyroidism as TSH 4.5, 10 mIU/L with normal fT4. The guidelines state: "Levothyroxine therapy is recommended for patients with TSH >10 mIU/L, and may be considered for patients with TSH 4.5, 10 mIU/L who are symptomatic or have positive TPO antibodies" [17].

Subclinical Hypothyroidism

Subclinical hypothyroidism (SCH) in childhood carries particular significance because TSH reference ranges differ from adult norms. In neonates, TSH can physiologically reach 20, 100 mIU/L within the first 30 minutes of life before falling to adult ranges within one week. Persistent TSH of 6, 10 mIU/L with normal fT4 in infants over two weeks of age warrants close monitoring; a 2020 Cochrane review found insufficient evidence to recommend universal treatment of SCH in children with TSH below 10 mIU/L when fT4 remains normal [18]. In adults, SCH affects an estimated 3 to 8% of the population, with higher prevalence in women over 60 [19].

Graves' Disease

Graves' disease is the most common cause of hyperthyroidism in children and adults, accounting for 60 to 80% of all hyperthyroid cases. It is an autoimmune condition in which TSH-receptor-stimulating antibodies (TRAb) activate the gland continuously, bypassing pituitary regulation entirely. Neonatal Graves' disease, a distinct condition from CH, affects infants born to mothers with active Graves' disease when maternal TRAb crosses the placenta and stimulates the fetal thyroid. It presents with tachycardia, irritability, and poor weight gain within the first week and resolves spontaneously as maternal antibodies clear over three to twelve weeks. Treatment in symptomatic neonates uses methimazole at 0.5 mg/kg/day and propranolol at 2 mg/kg/day in divided doses until antibody levels fall [20].

In adolescents and adults, first-line Graves' therapy uses methimazole at 0.2 to 0.5 mg/kg/day (maximum 30 mg/day), radioactive iodine (I-131) ablation, or surgical thyroidectomy, each with distinct risk profiles. The 2016 American Thyroid Association Graves' disease guideline notes that the 18-month remission rate after methimazole alone is approximately 40 to 60% in adults [21].

Iodine Nutrition and Thyroid Health Across the Life Course

Adequate iodine intake is the foundation of thyroid health for all age groups. The recommended dietary allowance (RDA) is 150 mcg/day for adults, 220 mcg/day during pregnancy, and 290 mcg/day while breastfeeding [22]. Globally, the WHO estimates that iodine deficiency disorders affect 2 billion people, making dietary iodization one of the most impactful public health interventions in history. In the United States, national iodized salt programs have maintained median urinary iodine at 144 mcg/L in non-pregnant adults, within the WHO adequate range of 100 to 199 mcg/L, though pregnant women remain at risk, with median urinary iodine of 125 mcg/L, below the pregnancy target of 150 to 249 mcg/L [23].

For infants with CH on levothyroxine, iodine adequacy in the nursing mother's diet or infant formula remains relevant because the thyroid gland, even if hypoplastic, may still contribute some baseline hormone output that depends on iodine substrate availability.

Genetic Testing and Family Counseling

Most CH cases (approximately 85%) are sporadic. Genetic testing is not part of routine newborn care but may be offered when a family history of thyroid dysgenesis or dyshormonogenesis exists, when multiple siblings are affected, or when syndromic features suggesting NKX2-1 mutations are present (the "brain-lung-thyroid syndrome" triad of CH, neonatal respiratory distress, and childhood-onset ataxia or chorea). Referral to a pediatric endocrinologist with molecular genetics support is appropriate in these scenarios. The recurrence risk for isolated thyroid dysgenesis in a subsequent sibling is approximately 2%, compared with up to 25% for autosomal recessive dyshormonogenesis [24].